Therapy News and Research

RSS

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

For two decades beginning in the late 1970’s through 2001, clinicians relied upon laser photocoagulation in the treatment of wet AMD caused by choroidal neovascularization. Attempts to obliterate the neovascular lesions often led to acute central visual loss and often, even with modest success, the lesions recurred with even more vision loss.

21 Jul 2015

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial.

21 Jul 2015

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Individuals with new-onset type 1 diabetes who took two courses of alefacept (Amevive®, Astellas Pharma Inc.) soon after diagnosis show preserved beta cell function after two years compared to those who received a placebo.

21 Jul 2015

Breast cancer survivors in Appalachia not taking life-saving follow-up treatment, new study finds

Nearly a third of breast cancer survivors in Appalachia are not taking the critical, potentially life-saving follow-up treatment - despite having insurance that would pay for it, a troubling new study has found.

21 Jul 2015

Scott & White Healthcare - Round Rock now offers fully integrative medicine services to Central Texans

Scott & White Healthcare - Round Rock is now offering integrative medicine services to Central Texans that include massage therapy and acupuncture at two of its regional clinics: Scott & White Clinic - Avery Ranch and Baylor Scott & White Clinic - Round Rock South.

21 Jul 2015

Managing Director of Messe Düsseldorf issues statement on upcoming MEDICA 2015

To get to the top is difficult; to stay at the top is even more difficult. Every athlete knows that and this also applies to the trade show business.

21 Jul 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

21 Jul 2015

New technique holds promise for improving glycoprotein-based pharmaceuticals

Researchers from the University of Copenhagen have discovered a way of improving biotech drugs. Better, cheaper and more effective drugs to combat cancer, arthritis and many other disorders.

21 Jul 2015

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report.

21 Jul 2015

New UTMB study finds no association between testosterone therapy and blood clots in veins

A new study from The University of Texas Medical Branch at Galveston of more than 30,000 commercially insured men is the first large comparative analysis to show that there is no link between testosterone therapy and blood clots in veins. The study found that middle-aged and older men who receive testosterone therapy are not at increased risk of this illness.

21 Jul 2015

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma.

20 Jul 2015

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

NDSU assistant professor receives NIH grant to study regulation of transporters in Gram-negative bacteria

Christopher Colbert, assistant professor of biochemistry at North Dakota State University, Fargo, has received a $348,000 grant award from the National Institute of General Medical Sciences of the National Institutes of Health to conduct research on structure-function relationships of iron transport and transcriptional regulation in Gram-negative bacteria.

20 Jul 2015

Researchers find evidence that directly links disrupted metabolism to fatal type of lymphoma

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio have found evidence that directly links disrupted metabolism (energy production in cells) to a common and often fatal type of lymphoma.

20 Jul 2015

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium.

20 Jul 2015

UofL conducts Phase I research study for children with relapsed tumors

Zach feels "pretty good." Sam wants to be "done with shots!" And Tyler finds it helps to "just keep thinking that at least I'm getting out of school." They are normal boys who had normal lives until cancer came into the picture. All have faced the disease for two years or more, with surgeries, chemotherapy and radiation treatments. All were diagnosed with various malignant solid tumors, went into remission and then relapsed.

17 Jul 2015

Rowan University, Bamboo Therapeutics partner to combat Canavan disease

Rowan University and Bamboo Therapeutics, Inc. have entered into an asset transfer agreement to commercialize a novel gene therapy for the treatment of Canavan disease. A rare but devastating neurological disease that tragically takes a child's life by age 10, Canavan disease is one of the most common and complex degenerative cerebral diseases in infants.

17 Jul 2015

UT Southwestern researchers find potential therapy to treat diabetes, nonalcoholic fatty liver disease

Reducing high concentrations of a fatty molecule that is commonly found in people with diabetes and nonalcoholic fatty liver disease rapidly improves insulin sensitivity, UT Southwestern Medical Center diabetes researchers have found.

17 Jul 2015

AESKU.DIAGNOSTICS offers new early prognostic marker for RA

Activity and outcome scores like DAS, DAS28, SDAI or CDAI, Larsen Score, etc. are commonly used but are time consuming and not practical in the early phase of rheumatoid arthritis (RA).

17 Jul 2015

Therapy News and Research

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Breast cancer survivors in Appalachia not taking life-saving follow-up treatment, new study finds

Scott & White Healthcare - Round Rock now offers fully integrative medicine services to Central Texans

Managing Director of Messe Düsseldorf issues statement on upcoming MEDICA 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

New technique holds promise for improving glycoprotein-based pharmaceuticals

Researchers successfully treat eczema patients using rheumatoid arthritis drug

New UTMB study finds no association between testosterone therapy and blood clots in veins

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

NeoGenomics announces launch of new germline cancer predisposition testing services

NDSU assistant professor receives NIH grant to study regulation of transporters in Gram-negative bacteria

Researchers find evidence that directly links disrupted metabolism to fatal type of lymphoma

Study findings provide basis for potential development of new methods to control HIV infection

UofL conducts Phase I research study for children with relapsed tumors

Rowan University, Bamboo Therapeutics partner to combat Canavan disease

UT Southwestern researchers find potential therapy to treat diabetes, nonalcoholic fatty liver disease

AESKU.DIAGNOSTICS offers new early prognostic marker for RA

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News